Abstract
The antitumor effects of an experimental chemoendocrine therapy combining a new pure antiestrogen ICI 182780 and 5-fluorouracil (5-FU) were studied on MCF-7 human breast cancer cells implanted in nude mice. ICI 182780 had a dose-dependent antitumor activity, which was potentiated by the concomitant use of 5-FU. When compared with the control group, the estrogen receptor (ER) level in the ICI 182780 group was lower and that in the combination group was markedly lower. Cell cycle analysis by flow cytometry (FCM) resulted in a lower percentage of S-phase cells (%S) in the treated mice. No significant difference was observed in the 5-FU concentrations in tumor cells, while the 5-FU content in RNA was significantly higher in the combination group. The changes in free thymidylate synthetase (TS) concentration indicated TS synthesis after the administration of 5-FU to be more greatly suppressed in the combination group than in the 5-FU group. These results suggest that ICI 182780 and 5-FU exert their combination effect mainly on ER-positive cells, and that the suppression of TS synthesis in tumor cells and the potentiation of the 5-FU-induced metabolic dysfunction of RNA are thus involved in the mode of action of this combination therapy.
Similar content being viewed by others
References
Furr BJ, Patterson JS, Richardson DN, Slater SR, Wakeling AE (1979) Tamoxifen. Pharmacological and biochemical properties of drug substances 2. American pharmaceutical association academy of pharmaceutical sciences. Washington, pp 355–399
Ashizawa T, Ishida H, Okabe M, Gomi K (1993) Effect of medroxyprogesterone acetate on antitumor efficacies and side effect on 5-fluorouracil (in Japanese with English abstract). Gan To Kagaku Ryoho 20:941–947
Harper MJK, Walpole AL (1966) Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 212:87
Boccardo F, Guarneri D, Rubagotti A, Casertelli GL, Bentivoglio G, Conte N, Campanella G, Gaggero G, Comelli G, Zanardi S, Nicolo G (1984) Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori 70:61–68
Fornander T, Rutqvist LE, Wilking N, Carstrom K, Schoultz BV (1993) Oestrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer. Eur J Cancer 29A:497–500
Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS (1991) Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450–1459
Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13:513–529
Wakeling AE (1993) The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 25:1–9
Parker MG (1993) Action of “pure” antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 26:131–137
Soule HD, Vazquez J, Long A, Albert S, Brennan M (1973) A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51:1409–1413
Takeuchi T (1995) Chemo- and endocrino-therapy of breast carcinoma xenografts in the dormant or exponential growth phase (in Japanese with English abstract). Nippon Geka Gakkai Zasshi (J Jpn Surg Soc) 96:379–387
Hanatani Y, Kubota T, Yamada Y, Tsuyuki K, Nakada M, Matsumoto S, Kumai K, Yoshino K, Ishibiki K, Abe O (1980) Experimental chemotherapy of human carcinomas serially transplanted to nude mice (in Japanese with English abstract). Nippon Gan Chiryo Gakkai Shi (J Jap Soc Cancer Ther) 15:1114–1120
Masuike T, Watanabe I, Takemoto Y (1985) Quantitative method of 5-fluorouracil and its metabolites in biological samples using high performance liquid chromatography (in Japanese with English abstract). Yakugaku Zasshi 105:1058–1064
Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH (1982) In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and- resistant murine colon adenocarcinoma. Cancer Res 42: 450–456
Masuike T, Kikuchi K, Saito A, Hashimoto T, Takemoto Y (1995) Determination of 5-fluorouracil incorporated into RNA in tissue using gas chromatography-mass spectrometry (in Japanese with English abstract). Antibiot Chemother 11:162–167
Cocconi G, De Lisi V, Boni C, Mori P, Malacarne P, Amadori D, Giovanelli E (1983) Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. Cancer 51:581–588
Kardinal CG, Perry MC, Weinberg V, Wood W, Ginsberg S, Raju RN (1983) Chemoendocrine therapyvs chemotherapy alone for advanced breast cancer in postmenopausal women: preliminary report of a randomized study. Breast Cancer Res Treat 3:365–371
Mouridsen HT, Rose C, Engelsman E, Sylvester R, Rotmensz N (1985) Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMFvs CMF plus tamoxifen. Eur J Cancer Clin Oncol 21:291–299
Viladiu P, Alonso MC, Avella A, Beltran M, Borras J, Ojeda B, Bosch FX (1985) Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial. Cancer 56:2745–2750
Falkson G, Falkson HC, Glidewell O, Weinberg V, Leone L, Holland JF (1979) Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy. Cancer 43:2215–2222
Cavalli F, Beer M, Marts G, Jungi WF, Alberto P, Obrecht JP, Mermillod B, Brunner KW (1983) Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss group for clinical cancer research. Br Med J 286:5–8
Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia (1986) A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol 4:186–193
Kiang DT, Gay J, Goldman A, Kennedy BJ (1985) A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 313:1241–1246
Watanabe O (1994) Experimental chemoendocrine therapy of human breast carcinoma xenograft serially transplanted into nude mice (in Japanese with English abstract). Nippon Geka Gakkai Zasshi (J Jpn Surg Soc) 95:263–270
Kubota T, Josui K, Ishibiki K, Abe O, Yamada Y, Asanuma F, Kawamura E, Kou J, Shiina E (1990) Experimental combined chemo- and endocrino-therapy of UFT and tamoxifen on human breast carcinoma xenografts serially transplanted into nude mice (in Japanese with English abstract). Nippon Gan Chiryo Gakkai Shi (J Jap Soc Cancer Ther) 25:2767–2773
Benz C, Santos G, Cadman ED (1983) Tamoxifen and 5-fluorouracil in breast cancer: modulation of cellular RNA. Cancer Res 43:5304–5308
Benz C, Cadman ED, Gwin J, Wu T, Amara J, Eisenfeld A, Dannies P (1983) Tamoxifen and 5-fluorouracil in breast cancer: cytotoxic synergism in vitro. Cancer Res 43:5298–5303
Sato Y (1989) Experimental studies on the effect of chemoendocrine therapy on DMBA induced rat mammary cancer (in Japanese with English abstract). J Nihon Univ Med Assoc 48:413–421
Yamanoto H, Morimoto T, Monden Y (1989) Effect of chemoendocrine therapy on DMBA-induced rat mammary carcinoma (in Japanese with English abstract). Nippon Geka Gakkai Zasshi (J Jpn Surg Soc) 90:1786–1792
Kondo T, Imaizumi M, Taguchi T, Abe O, Hattori T, Wakui A, Kitano M (1987) A model for sensitivity determination of anticancer agents against human cancer using nude mice (in Japanese with English abstract). Gan To Kagaku Ryoho 14:680–686
Koh J (1988) Experimental chemo- and chemoendocrine therapy of human breast carcinomas serially transplanted into nude mice (in Japanese with English abstract). Nippon Geka Gakkai Zasshi (J Jpn Surg Soc) 89:91–102
Suzuki M (1992) Flow cytometric analysis of effects of chemohormonal agents on the cell cycle distribution of MCF-7 cells (in Japanese with English abstract). Nippon Geka Gakkai Zasshi (J Jpn Surg Soc) 93:71–80
Today RA, Crissman HA (1972) Use of flow microflurometry in detailed analysis of effects of chemical agents on cell cycle progression. Cancer Res 32:2726–2732
Nakamura A (1988) Experimental and clinical study on flow cytometric DNA analysis of human breast carcinoma (in Japanese with English abstract). Nippon Geka Gakkai Zasshi (J Jpn Surg Soc) 89:737–746
Darnenberg PV (1977) Thymidylate synthetase—a target engyme in cancer chemotherapy. Biochim Biophys Acta 473:73–92
Cory JG, Breland JC, Carter GL (1979) Effect of 5-fluorouracil on RNA metabolism in Novikoff hepatoma cells. Cancer Res 39:4905–4913
Ardalan B, Cooney DA, Jayaram HN, Carrico CK, Glazer RI, Macdonald J, Schein PS (1980) Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil. Cancer Res 40:1431–1437
Ueki H (1987) Synergistic effect of cell kinetics-directed chemoendocrine therapy on experimental mammary tumors (in Japanese with English abstract). Nippon Geka Gakkai Zasshi (J Jpn Surg Soc) 88: 1576–1583
Maybaum J, Ullman B, Mandel HG, Day JL, Sadee W (1980) Regulation of RNA- and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells. Cancer Res 40:4209–4215
Kubota T, Fujita S, Kodaira S, Yamamoto T, Josui K, Arisawa Y, Suto A, Ishibiki K, Abe O, Mabuchi K, Fuse M (1991) Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition. Jpn J Cancer Res 82:476–482
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ogasawara, Y., Doihara, H., Shiroma, K. et al. Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice. Surg Today 29, 149–156 (1999). https://doi.org/10.1007/BF02482240
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02482240